David Kerstein

2.8k total citations · 1 hit paper
56 papers, 1.4k citations indexed

About

David Kerstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, David Kerstein has authored 56 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 11 papers in Hematology. Recurrent topics in David Kerstein's work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (23 papers) and Colorectal Cancer Treatments and Studies (20 papers). David Kerstein is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (23 papers) and Colorectal Cancer Treatments and Studies (20 papers). David Kerstein collaborates with scholars based in United States, Spain and South Korea. David Kerstein's co-authors include Corey J. Langer, Scott Gettinger, D. Ross Camidge, Frank G. Haluska, Marcello Tiseo, Myung‐Ju Ahn, Rudolf M. Huber, Howard West, Maximilian J. Hochmair and William M. Reichmann and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

David Kerstein

54 papers receiving 1.4k citations

Hit Papers

Brigatinib in Patients With Crizotinib-Refractory Anaplas... 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
    2017 430 citations Dong‐Wan Kim, Marcello Tiseo et al. Journal of Clinical Oncology profile →

Peers

David Kerstein
Edward M. Chan United States
Vanessa Giannone United States
Michele C. Azada United States
Ira A. Oliff United States
V. A. Miller United States
H. Spiridonidis United States
Thanyanan Reungwetwattana Thailand
Yuichi Sakamori Japan
Martina Uttenreuther‐Fischer Germany
Edward M. Chan United States
David Kerstein
Citations per year, relative to David Kerstein David Kerstein (= 1×) peers Edward M. Chan

Countries citing papers authored by David Kerstein

Since Specialization
Citations

This map shows the geographic impact of David Kerstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kerstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kerstein more than expected).

Fields of papers citing papers by David Kerstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kerstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kerstein. The network helps show where David Kerstein may publish in the future.

Co-authorship network of co-authors of David Kerstein

This figure shows the co-authorship network connecting the top 25 collaborators of David Kerstein. A scholar is included among the top collaborators of David Kerstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kerstein. David Kerstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hanley, Michael J., David Kerstein, Meera Tugnait, et al.. (2023). Brigatinib pharmacokinetics in patients with chronic hepatic impairment. Investigational New Drugs. 41(3). 402–410. 3 indexed citations
2.
George, Suzanne, William D. Tap, Margaret von Mehren, et al.. (2023). Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 41(16_suppl). e23508–e23508. 2 indexed citations
3.
Gupta, Neeraj, Michael J. Hanley, David Kerstein, et al.. (2021). Effect of severe renal impairment on the pharmacokinetics of brigatinib. Investigational New Drugs. 39(5). 1306–1314. 7 indexed citations
4.
Gupta, Neeraj, Xiaohui Wang, Elliot Offman, et al.. (2020). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical Pharmacokinetics. 60(2). 235–247. 15 indexed citations
5.
Ng, Terry L., Narayana I. Narasimhan, Neeraj Gupta, et al.. (2020). Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. Journal of Thoracic Oncology. 15(7). 1190–1199. 26 indexed citations
6.
Huber, Rudolf M., Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, et al.. (2019). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology. 15(3). 404–415. 101 indexed citations
7.
Kawata, Ariane K., William R. Lenderking, David Kerstein, et al.. (2019). Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study. Journal of Medical Economics. 22(9). 924–935. 9 indexed citations
8.
Neal, Joel W., Robert C. Doebele, Gregory J. Riely, et al.. (2018). P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC. Journal of Thoracic Oncology. 13(10). S599–S599. 24 indexed citations
9.
Reckamp, Karen L., et al.. (2017). Prognostic factors in crizotinib (CRZ)-resistant anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) patients (Pts). Annals of Oncology. 28. ii38–ii39. 1 indexed citations
10.
Tiseo, Marcello, Rudolf M. Huber, Maximilian J. Hochmair, et al.. (2017). Brigatinib in ALK+ NSCLC pts with intracranial CNS metastases in 2 clinical trials. Annals of Oncology. 28. ii31–ii31. 2 indexed citations
11.
12.
Gettinger, Scott, Dong‐Wan Kim, Marcello Tiseo, et al.. (2017). OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials. Journal of Thoracic Oncology. 12(1). S273–S274. 4 indexed citations
13.
Bazhenova, Lyudmila, Scott Gettinger, Corey J. Langer, et al.. (2017). Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial. Annals of Oncology. 28. v479–v480. 5 indexed citations
14.
Gettinger, Scott, Lyudmila Bazhenova, Corey J. Langer, et al.. (2016). Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet Oncology. 17(12). 1683–1696. 261 indexed citations
15.
16.
Rosell, Rafael, Scott Gettinger, Lyudmila Bazhenova, et al.. (2016). 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. Journal of Thoracic Oncology. 11(4). S114–S114. 28 indexed citations
17.
Tiseo, Marcello, Myung‐Ju Ahn, Karen L. Reckamp, et al.. (2016). Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial. Annals of Oncology. 27. iv4–iv4. 1 indexed citations
18.
Bazhenova, Lyudmila, Scott Gettinger, Corey J. Langer, et al.. (2016). Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial. Annals of Oncology. 27. vi418–vi418. 2 indexed citations
19.
Kerstein, David, Scott Gettinger, Corey J. Langer, et al.. (2015). Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases. Annals of Oncology. 26. i57–i57. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward M. Chan Breakdown of academic impact, for papers by Vanessa Giannone Breakdown of academic impact, for papers by Michele C. Azada Breakdown of academic impact, for papers by Ira A. Oliff Breakdown of academic impact, for papers by V. A. Miller Breakdown of academic impact, for papers by H. Spiridonidis Breakdown of academic impact, for papers by Thanyanan Reungwetwattana Breakdown of academic impact, for papers by Yuichi Sakamori Breakdown of academic impact, for papers by Martina Uttenreuther‐Fischer
Rankless by CCL
2026